Real World Data on Gi(l)Otrif® Dose Adjustment

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Carcinoma, Non-Small-Cell Lung

Study type

Observational

Funder types

Industry

Identifiers

NCT02751879
1200.270

Details and patient eligibility

About

This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.

Enrollment

228 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age = 18 years
  • Patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), tyrosine kinase inhibitors (TKI)-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
  • Signed and dated written informed consent per regulations. (Exemption of a written informed consent for retrospective observational studies in some countries per local regulations and legal requirements.)

Exclusion criteria

  • Any contraindication to Gi(l)otrif® as specified in label.
  • Patients with uncommon mutations are excluded as uncommon mutations are not within label in all participating countries (e.g. USA).
  • Patients still on treatment with Gi(l)otrif® will be excluded unless treatment period is > or = 6 months.
  • Patients treated with Gi(l)otrif® within an interventional trial.

Trial design

228 participants in 1 patient group

Non small cell lung cancer (NSCLC)
Description:
patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label

Trial documents
2

Trial contacts and locations

29

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems